DK1237539T3 - Oral oplösning indeholdende galanthamin og et södemiddel - Google Patents

Oral oplösning indeholdende galanthamin og et södemiddel

Info

Publication number
DK1237539T3
DK1237539T3 DK00975872T DK00975872T DK1237539T3 DK 1237539 T3 DK1237539 T3 DK 1237539T3 DK 00975872 T DK00975872 T DK 00975872T DK 00975872 T DK00975872 T DK 00975872T DK 1237539 T3 DK1237539 T3 DK 1237539T3
Authority
DK
Denmark
Prior art keywords
sweetener
solution containing
oral solution
containing galanthamine
galanthamine
Prior art date
Application number
DK00975872T
Other languages
Danish (da)
English (en)
Inventor
Tony Mathilde J Kempen
Proost Eddy A Josee De
Marc Karel Jozef Jans Francois
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of DK1237539T3 publication Critical patent/DK1237539T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
DK00975872T 1999-10-26 2000-10-16 Oral oplösning indeholdende galanthamin og et södemiddel DK1237539T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99203512 1999-10-26

Publications (1)

Publication Number Publication Date
DK1237539T3 true DK1237539T3 (da) 2006-02-27

Family

ID=8240778

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00975872T DK1237539T3 (da) 1999-10-26 2000-10-16 Oral oplösning indeholdende galanthamin og et södemiddel

Country Status (30)

Country Link
EP (1) EP1237539B1 (cs)
JP (1) JP2003512415A (cs)
KR (1) KR100502391B1 (cs)
CN (1) CN1200691C (cs)
AR (1) AR026243A1 (cs)
AT (1) ATE306904T1 (cs)
AU (1) AU780826C (cs)
BG (1) BG65792B1 (cs)
BR (1) BR0015025A (cs)
CA (1) CA2388830C (cs)
CZ (1) CZ301996B6 (cs)
DE (1) DE60023341T2 (cs)
DK (1) DK1237539T3 (cs)
EA (1) EA005683B1 (cs)
EE (1) EE05230B1 (cs)
ES (1) ES2250211T3 (cs)
HK (1) HK1049619A1 (cs)
HR (1) HRP20020332B1 (cs)
HU (1) HUP0203484A3 (cs)
IL (2) IL149310A0 (cs)
IS (1) IS2628B (cs)
MX (1) MXPA02004149A (cs)
NO (1) NO332096B1 (cs)
PL (1) PL201694B1 (cs)
SI (1) SI1237539T1 (cs)
SK (1) SK285643B6 (cs)
TW (1) TW592725B (cs)
UA (1) UA76095C2 (cs)
WO (1) WO2001030318A1 (cs)
ZA (1) ZA200203313B (cs)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030162770A1 (en) * 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
JP2007502297A (ja) * 2003-08-13 2007-02-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ コリンエステラーゼ阻害剤を用いる睡眠障害の処置
US20050191349A1 (en) * 2003-12-31 2005-09-01 Garth Boehm Galantamine formulations
US8709521B2 (en) * 2007-05-22 2014-04-29 The Coca-Cola Company Sweetener compositions having enhanced sweetness and improved temporal and/or flavor profiles
WO2012102832A1 (en) * 2011-01-27 2012-08-02 Neuren Pharmaceuticals Limited Treatment of autism spectrum disorderes using glycyl-l-2-methylprolyl-l-glutamic acid
WO2014059363A1 (en) * 2012-10-11 2014-04-17 Antrim Pharmaceuticals Llc Oral solution formulations of aripiprazole
JP6457582B2 (ja) * 2017-04-14 2019-01-23 エルメッド エーザイ株式会社 ガランタミン含有医薬組成物、並びに医薬組成物におけるガランタミンの苦味抑制方法、及びガランタミンの苦味抑制剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
US6323195B1 (en) * 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
JPH10273435A (ja) * 1997-01-29 1998-10-13 Fujisawa Pharmaceut Co Ltd 内服用液剤

Also Published As

Publication number Publication date
NO20022003L (no) 2002-06-18
ZA200203313B (en) 2003-11-26
BG65792B1 (bg) 2009-12-31
WO2001030318A1 (en) 2001-05-03
HRP20020332A2 (en) 2004-02-29
SK285643B6 (sk) 2007-05-03
HRP20020332B1 (en) 2011-02-28
PL201694B1 (pl) 2009-04-30
MXPA02004149A (es) 2002-10-17
UA76095C2 (en) 2006-07-17
HUP0203484A2 (hu) 2003-02-28
CN1382037A (zh) 2002-11-27
EE05230B1 (et) 2009-12-15
EP1237539A1 (en) 2002-09-11
CZ20021329A3 (cs) 2002-08-14
DE60023341D1 (de) 2006-03-02
CA2388830A1 (en) 2001-05-03
ES2250211T3 (es) 2006-04-16
EA005683B1 (ru) 2005-04-28
HUP0203484A3 (en) 2004-12-28
BR0015025A (pt) 2002-06-18
PL362849A1 (en) 2004-11-02
KR100502391B1 (ko) 2005-07-19
NO20022003D0 (no) 2002-04-26
EP1237539B1 (en) 2005-10-19
IS2628B (is) 2010-05-15
KR20020026010A (ko) 2002-04-04
EA200200486A1 (ru) 2002-10-31
CN1200691C (zh) 2005-05-11
IS6291A (is) 2002-02-28
CZ301996B6 (cs) 2010-09-01
AU1384901A (en) 2001-05-08
TW592725B (en) 2004-06-21
AU780826B2 (en) 2005-04-21
EE200200213A (et) 2003-06-16
SK5302002A3 (en) 2002-10-08
ATE306904T1 (de) 2005-11-15
SI1237539T1 (sl) 2006-04-30
HK1049619A1 (en) 2003-05-23
AR026243A1 (es) 2003-02-05
NO332096B1 (no) 2012-06-18
DE60023341T2 (de) 2006-07-27
IL149310A (en) 2006-12-10
IL149310A0 (en) 2002-11-10
JP2003512415A (ja) 2003-04-02
CA2388830C (en) 2006-09-19
AU780826C (en) 2006-02-16
BG106534A (en) 2002-12-29

Similar Documents

Publication Publication Date Title
NO2008001I1 (no) Vildagliptin og farmasoytisk akseptable salter derav
GB2368022B (en) Portable oral irrigator
HUP0203204A3 (en) Oral dosage forms
DK1454907T3 (da) Quninazolin og pyridopyrmidin-derivativer
IS5433A (is) Sýklískar amínafleiður og notkun þeirra sem lyf
EE200200012A (et) Suukaudselt manustatav maskeeritud maitsega vedelpreparaat
DE69615887D1 (de) Oral anzuwendende Arzneizubereitung enthaltend Olanzapin
DK1009454T3 (da) Dental bedövelsesmiddel og tilförselsinjektionsenhed
DE69715691D1 (de) Mundhygienegerät
DK200300344U1 (da) Amlodipinmaleat og farmaceutisk præparat indeholdende amlodipinmaleat
FR2800357B1 (fr) Verseur ameliore et capsule a verseur incorpore
NO20003916D0 (no) Benzotiadiazoler og derivater
DE69921459D1 (de) Vorgefertigte zahnseidevorrichtung
DK1068238T3 (da) Integrinheterodimer og subunit deraf
NO20006576L (no) Et substituert triazol-pyridazinderivat og farmasöytiske preparater fremstilt av dette
DK1237539T3 (da) Oral oplösning indeholdende galanthamin og et södemiddel
ATE246502T1 (de) Arzneiformen enthaltend carvedilol
ID30397A (id) Larutan oral prukaloprida
GB9919574D0 (en) Dental floss devices
NO20013863D0 (no) Liposompreparat og fremgangsmate for a administrere en bestralingsfolsom forbindelse
DK200000164A (da) Afskærmet kredsløbsindretning i et høreapparat og høreapparat
HK1047232A1 (zh) 口服劑型
ITBO940469A0 (it) Filo interdentale a resca
FR2789764B1 (fr) Analyseur d'impulsion de rayonnement unique et breve
IL132006A0 (en) Stable pharmaceuticl oral dosage forms